Children's Hospital at London Health Sciences Centre

Brain Cancer Canada Awards CAD 50,000 Grant for Innovative Research to Improve Brain Cancer Diagnosis and Treatment

Retrieved on: 
Thursday, May 4, 2023
Canada, Glioblastoma, London Health Sciences Centre, Cancer, DRS, Research, Brain, Brain tumor, Patient, Hospital, Diagnosis, Children's Hospital at London Health Sciences Centre, Caregiver, Medical imaging

TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $50,000 grant to support research on more effective diagnosis and treatment for adult brain cancer patients.

Key Points: 
  • TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $50,000 grant to support research on more effective diagnosis and treatment for adult brain cancer patients.
  • For Brain Cancer Canada, a leading charity supporting brain cancer research and patient advocacy, this research project is an opportunity to make a tangible difference in the lives of patients.
  • “We are thrilled to support this groundbreaking research project,” said Angela Scalisi, Chair of Brain Cancer Canada.
  • Brain Cancer Canada board director Marc Peeters highlighted the need for innovation in fighting brain cancer.

Global Epigenetics Market Analysis & Forecasts Report, 2016-2021, 2021-2026F, 2031F Featuring Major Players - Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, & Active Motif - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Biotechnology, Genetics, Health, EFTA, Growth, European Commission–AstraZeneca COVID-19 vaccine dispute, Diagnosis, CDC, Union, Prevalence, Korea Disease Control and Prevention Agency, European Free Trade Association, Joint Research Centre, Gene, Acceleration, DNA, LHSC, VUS, Children's Hospital at London Health Sciences Centre, Genomics, European Commission, London Health Sciences Centre, Cancer, Genetic testing, Exact sciences, DNA methylation, Acquisition, Renewable energy, Vaccine, Pharmaceutical industry, EU

The growing prevalence of cancer and other diseases is significantly driving the growth of the epigenetics market.

Key Points: 
  • The growing prevalence of cancer and other diseases is significantly driving the growth of the epigenetics market.
  • The regions covered in the epigenetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The key players in the epigenetics sector are focusing on developing various technologically advanced products and services to strengthen their position in the market.
  • The countries covered in the epigenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Vena Medical Celebrates First Procedures with Category-Defining Balloon Distal Access Catheter™ (BDAC)

Retrieved on: 
Tuesday, August 16, 2022
Xchange, FDA, Journal of NeuroInterventional Surgery, The Ottawa Hospital, Principal, LVO, CEO, GLOBE, Technology, American Journal of Neuroradiology, Children's Hospital at London Health Sciences Centre, DRS, Thrombectomy, Neuroradiology, University of Alberta Hospital, Recce (filmmaking), LHSC, Vein, Patient, Thrombus, Stroke, Neurology, American Journal, Teaching hospital, MDSAP, Vena, London Health Sciences Centre, Physician, Journal, Foothills Medical Centre, University, TOH, AIS, MIX, Artery, Medical device

The Vena BDAC combines the balloon guide catheters and distal access catheters that are currently used in thrombectomy to remove clots from the brains of stroke victims.

Key Points: 
  • The Vena BDAC combines the balloon guide catheters and distal access catheters that are currently used in thrombectomy to remove clots from the brains of stroke victims.
  • Other centres included in the VANISH trial and/or evaluating the Vena BDAC are London Health Sciences Centre-University Hospital (Drs.
  • Vena Medical, an ISO 13485 and MDSAP certified company, is creating a suite of tools to change the way physicians perform minimally invasive neurosurgery, starting with the Vena Balloon Distal Access Catheter, currently available in Canada.
  • Vena Medical is part of the MIX (Medical Innovation Xchange) group of companies https://medicalinnovationxchange.com .

Vena Medical Celebrates First Procedures with Category-Defining Balloon Distal Access Catheter™ (BDAC)

Retrieved on: 
Tuesday, August 16, 2022
Xchange, FDA, Journal of NeuroInterventional Surgery, The Ottawa Hospital, Principal, LVO, CEO, GLOBE, Technology, American Journal of Neuroradiology, Children's Hospital at London Health Sciences Centre, DRS, Thrombectomy, Neuroradiology, University of Alberta Hospital, Recce (filmmaking), LHSC, Vein, Patient, Thrombus, Stroke, Neurology, American Journal, Teaching hospital, MDSAP, Vena, London Health Sciences Centre, Physician, Journal, Foothills Medical Centre, University, TOH, AIS, MIX, Artery, Medical device

The Vena BDAC combines the balloon guide catheters and distal access catheters that are currently used in thrombectomy to remove clots from the brains of stroke victims.

Key Points: 
  • The Vena BDAC combines the balloon guide catheters and distal access catheters that are currently used in thrombectomy to remove clots from the brains of stroke victims.
  • Other centres included in the VANISH trial and/or evaluating the Vena BDAC are London Health Sciences Centre-University Hospital (Drs.
  • Vena Medical, an ISO 13485 and MDSAP certified company, is creating a suite of tools to change the way physicians perform minimally invasive neurosurgery, starting with the Vena Balloon Distal Access Catheter, currently available in Canada.
  • Vena Medical is part of the MIX (Medical Innovation Xchange) group of companies https://medicalinnovationxchange.com .